Literature DB >> 6253509

Kirsten murine sarcoma virus transformed cell lines and a spontaneously transformed rat cell-line produce transforming factors.

B Ozanne, R J Fulton, P L Kaplan.   

Abstract

We have examined culture fluids from a variety of Kirsten murine sarcoma virus (KiMSV) transformed rat and mouse cells for the presence of factors which induce normal Rat-1 cells to assume the transformed phenotype. All KiMSV transformants produced transforming factor (TF). Revertants of KiMSV transformed rat or mouse failed to release TF as did normal rat or mouse cells. Cells transformed by a temperature sensitive mutant of KiMSV produced TF at the permissive temperature but not at the nonpermissive temperature. Further, cells from a spontaneous transformant of Rat-1 cells also produced TF. TF is a small polypeptide which competes for the epidermal growth factor receptor. Its effect upon normal cells is reversible and requires de novo RNA and protein synthesis. Cells treated with TF lose the actin fibers observed in normal fibroblasts, assume a transformed cell morphology, become anchorage independent for growth, grow in low concentrations of serum, grow to a high cell density, and have an increased rate of hexose uptake.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6253509     DOI: 10.1002/jcp.1041050118

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  51 in total

1.  Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells.

Authors:  M D Sklar; E Thompson; M J Welsh; M Liebert; J Harney; H B Grossman; M Smith; E V Prochownik
Journal:  Mol Cell Biol       Date:  1991-07       Impact factor: 4.272

2.  Transformation stimulates glucose transporter gene expression in the absence of protein kinase C.

Authors:  Y Hiraki; A Garcia de Herreros; M J Birnbaum
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

3.  The proliferative and morphologic responses of a colon carcinoma cell line (LIM 1215) require the production of two autocrine factors.

Authors:  A M Sizeland; A W Burgess
Journal:  Mol Cell Biol       Date:  1991-08       Impact factor: 4.272

4.  The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3.

Authors:  C Cordon-Cardo; P Tapley; S Q Jing; V Nanduri; E O'Rourke; F Lamballe; K Kovary; R Klein; K R Jones; L F Reichardt
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

5.  Altered processing of a major secreted phosphoprotein correlates with tumorigenicity in Rous sarcoma virus-transformed mammalian cells.

Authors:  I Chackalaparampil; D Banerjee; Y Poirier; B B Mukherjee
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

Review 6.  Calcium, cyclic AMP and protein kinase C--partners in mitogenesis.

Authors:  J F Whitfield; J P Durkin; D J Franks; L P Kleine; L Raptis; R H Rixon; M Sikorska; P R Walker
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

7.  Possible involvement of normal p21 H-ras in the insulin/insulinlike growth factor 1 signal transduction pathway.

Authors:  B M Burgering; A J Snijders; J A Maassen; A J van der Eb; J L Bos
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

8.  Transforming growth factor(s) production enables cells to grow in the absence of serum: an autocrine system.

Authors:  P L Kaplan; M Anderson; B Ozanne
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

9.  Malignant transformation of murine fibroblasts by a human c-Ha-ras-1 oncogene does not require a functional epidermal growth factor receptor.

Authors:  I A McKay; P Malone; C J Marshall; A Hall
Journal:  Mol Cell Biol       Date:  1986-10       Impact factor: 4.272

10.  Epidermal growth factor receptor expression on oral mucosa dysplastic epithelia and squamous cell carcinomas.

Authors:  M E Christensen; M H Therkildsen; B L Hansen; H Albeck; G N Hansen; P Bretlau
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.